Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Baxter
Merck
Medtronic
McKinsey

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Details for Patent: 8,367,102


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,367,102 protect, and when does it expire?

Patent 8,367,102 protects ABSORICA and is included in one NDA.

This patent has twelve patent family members in nine countries.

Summary for Patent: 8,367,102
Title:Pharmaceutical semi-solid composition of isotretinoin
Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
Inventor(s): Vanderbist; Francis (Beersel, BE), Servais; Cecile (Malonne, BE), Baudier; Phillippe (Uccle, BE)
Assignee: Galephar Pharmaceutical Research, Inc. (Juncos, PR)
Application Number:11/892,363
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,367,102
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,367,102

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-001 May 25, 2012 AB2 RX Yes No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial TREATMENT OF A SKIN DISORDER ⤷  Sign up for a Free Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-002 May 25, 2012 AB2 RX Yes No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial TREATMENT OF A SKIN DISORDER ⤷  Sign up for a Free Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-005 Aug 15, 2014 AB2 RX Yes No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial TREATMENT OF A SKIN DISORDER ⤷  Sign up for a Free Trial
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-003 May 25, 2012 AB2 RX Yes No ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial TREATMENT OF A SKIN DISORDER ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,367,102

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Belgium2000/0111Sep 22, 2000

International Family Members for US Patent 8,367,102

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 270544 ⤷  Sign up for a Free Trial
Australia 8943801 ⤷  Sign up for a Free Trial
Brazil 102013032172 ⤷  Sign up for a Free Trial
Canada 2423170 ⤷  Sign up for a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Harvard Business School
McKesson
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.